The electronic structure of transition meatal oxides is in the predominant position among mostly central reactions, such as oxygen electroncatalysis, for the applications in energy storage. Herein, cobalt‐based catalysts are developed by taking the advantage of the strong electronegativity of halogen elements, whose activity and stability are also guaranteed. A “theory–calculation–experiment” research system is proposed to sort out the relationship between the electronegativity of heteroatoms and the electronic structure of layered CoO/F, CoO/Cl, and CoO/Br, for the electrochemical oxygen evolution reaction (OER). Experiments corresponding to calculations also verify that the stronger the electronegativity of the halide ions in the cobalt oxide catalyst, the more obvious the improvement of OER performance. By understanding the electronegative screening of halogen modification, a new perspective on designing principles for water‐splitting devices based on bandgap‐engineered metal oxides is proposed.

Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, clinical characteristics, and treatment response compared to tumors with receptor tyrosine kinase protein (KIT) mutations (60–70%). Many clinical studies have investigated the use of tyrosine kinase inhibitors mainly in patients with KIT mutations; however, there is a lack of attention to the PDGFRA-mutated molecular subtype. The main effective inhibitors of PDGFRA are ripretinib, avapritinib, and crenolanib, and their mechanisms and efficacy in GIST (as confirmed in clinical trials) are described in this review. Some multi-targeted tyrosine kinase inhibitors with inhibitory effects on this molecular subtype are also introduced and summarized in this paper. This review focuses on PDGFRA-mutated GISTs, introduces their clinical characteristics, downstream molecular signaling pathways, and existing resistance mechanisms. We focus on the most recent literature that describes the development of PDGFRA inhibitors and their use in clinical trials, as well as the potential benefits from different combination therapy strategies.

No abstract

Oxygen reduction reaction (ORR) catalysts are critical components for the development of high‐efficiency fuel cells and metal‐air batteries. Supported PtCo alloy nanoparticles (NPs) with modified surface properties and reactivity through ligand, strain and/or ensemble effects are regarded as promising inexpensive low‐Pt candidates. Herein, we report an annealing‐free assembly of PtCo nanoparticles anchored on nitrogen‐doped mesoporous carbon (PtCo@NMC) for advanced ORR electrocatalysis in both alkaline and acidic electrolytes. Compared with the commercial Pt/C catalyst, the half‐wave potential (E1/2) values of PtCo@NMC increase to 0.93–0.94 V (Vs. RHE) and positively shift by approximately 45 mV. Moreover, the annealing‐induced degradation stems from agglomeration and growth of alloy NPs. Considering the excellent long‐term durability according to both chronoamperometry (CA) and accelerated durability tests (ADTs), we demonstrate practical application with enhanced performance in electrochemical energy devices, such as a primary Zn–air battery assembled with PtCo@NMC cathode.

No abstract